Fostamatinib
Brand names: Tavalisse Ā· Active ingredient: Fostamatinib
In short: TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
What is Fostamatinib used for?
TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Fostamatinib dosage
Initiate TAVALISSE at a dose of 100 mg taken orally twice daily. After a month, if platelet count has not increased to at least 50 Ć 109/L, increase TAVALISSE dose to 150 mg twice daily.
Use the lowest dose of TAVALISSE to achieve and maintain a platelet count at least 50 Ć 109/L as necessary to reduce the risk of bleeding.
TAVALISSE may be taken with or without food. In the case of a missed dose of TAVALISSE, instruct patients to take their next dose at its regularly scheduled time.
After obtaining baseline assessments:
Monitor CBCs, including platelet counts, monthly until a stable platelet count (at least 50 Ć 109/L) is achieved. Thereafter, continue to monitor CBCs, including neutrophils, regularly.
Monitor liver function tests (LFTs) (e.g., ALT, AST, and bilirubin) monthly.
Monitor blood pressure every 2 weeks until establishment of a stable dose, then monthly thereafter.
TAVALISSE dose modification is recommended based on individual safety and tolerability. Management of some adverse reactions may require dose-interruption, reduction, or discontinuation.
A dose reduction schedule is provided in Table 1, based on daily dose. For example, if a patient is on the maximum dose at the time of an adverse reaction, the first dose reduction would be from 300 mg/day to 200 mg/day.
Daily Dose | Administered as:
AM | PM
300 mg/day | 150 mg | 150 mg
200 mg/day | 100 mg | 100 mg
150 mg/day | 150 mgOnce daily TAVALISSE should be taken in the morning. | ---
100 mg/dayIf further dose reduction below 100 mg/day is required, discontinue TAVALISSE. | 100 mg | ---
The recommended dose modifications for adverse reactions are provided in Table 2.
Adverse Reaction | Recommended Action
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BP = blood pressure; BL = bilirubin; ULN = upper limit of normal; LFT = liver function tests (AST, ALT, total BL with fractionation if elevated, alkaline phosphatase); AST/ALT = AST or ALT
Hypertension
Stage 1: systolic between 130-139 or diastolic between 80-89 mmHg | Initiate or increase dosage of antihypertensive medication for patients with increased cardiovascular risk, and adjust as needed until BP is controlled.
If the BP target is not met after 8 weeks, reduce TAVALISSE to next lower daily dose .
Stage 2: systolic at least 140 or diastolic at least 90 mmHg | Initiate or increase dosage of antihypertensive medication, and adjust as needed until BP is controlled.
If BP remains 140/90 mmHg or higher for more than 8 weeks, reduce TAVALISSE to next lower daily dose .
If BP remains 160/100 mmHg or higher for more than 4 weeks despite aggressive antihypertensive therapy, interrupt or discontinue TAVALISSE.
Hypertensive crisis: systolic over 180 and/or diastolic over 120 mmHg | Interrupt or discontinue TAVALISSE. ā¦
How to take Fostamatinib ā instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Hypertension: Inform patients that periodic monitoring of their blood pressure is required, as high blood pressure has occurred in patients taking TAVALISSE. Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension .
Hepatotoxicity: Inform patients that periodic monitoring of their liver enzymes is required, and any elevations (which may indicate liver injury) will be managed appropriately, including interruption, reduction, or discontinuation of TAVALISSE .
Diarrhea: Advise patients to use supportive care measures, and if diarrhea becomes severe, it may necessitate interruption, reduction, or discontinuation of TAVALISSE .
Neutropenia: Inform patients that monitoring of their complete blood counts is required, and a decrease in neutrophils may necessitate interruption, reduction, or discontinuation of TAVALISSE . ā¦
Warnings & precautions
Do not take this medicine if: None.
Hypertension can occur with TAVALISSE treatment; hypertensive crisis occurred in 1% of patients. Patients with pre-existing hypertension may be more susceptible to the hypertensive effects of TAVALISSE.
Monitor blood pressure every 2 weeks until stable, then monthly and adjust or initiate antihypertensive therapy to ensure maintenance of blood pressure control during TAVALISSE therapy. If increased blood pressure persists despite appropriate therapy, TAVALISSE interruption, reduction or discontinuation may be necessary .
Elevated liver function tests (LFTs), mainly ALT and AST, can occur with TAVALISSE.
In the placebo-controlled studies, laboratory testing showed maximum ALT/AST levels more than 3 Ć the upper limit of normal (ULN) in 9% of patients receiving TAVALISSE . For most patients, transaminases recovered to baseline levels within 2 to 6 weeks of dose-modification.
Monitor liver function tests monthly during treatment. If ALT or AST increase more than 3 Ć ULN, manage hepatotoxicity using TAVALISSE interruption, reduction, or discontinuation .
Diarrhea occurred in 31% of patients treated with TAVALISSE. Severe diarrhea occurred in 1% of patients treated with TAVALISSE. Monitor patients for the development of diarrhea. Manage diarrhea using supportive care measures, including dietary changes, hydration and/or antidiarrheal medication, early after the onset of symptoms. Interrupt, dose reduce, or discontinue TAVALISSE if diarrhea becomes severe (Grade 3 or above) .
Neutropenia occurred in 6% of patients treated with TAVALISSE; febrile neutropenia occurred in 1% of patients.
Monitor the ANC monthly, and for infection during treatment. Manage toxicity with TAVALISSE interruption, reduction or discontinuation . ā¦
Fostamatinib side effects
The following clinically important adverse reactions, that can become serious are described elsewhere in the labeling:
Hypertension
Hepatotoxicity
Diarrhea
Neutropenia
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
TAVALISSE was studied in two randomized, double-blind, placebo-controlled trials that were identical in design. The data described below reflect exposure to TAVALISSE in 102 patients with chronic ITP who had received one or more prior ITP treatment(s). Groups were stratified with respect to splenectomy and severity of thrombocytopenia. Patients randomized to the TAVALISSE arm received 100 mg orally twice daily. Based upon platelet count and tolerability, if a patient's platelet count did not increase to at least 50 Ć 109/L, the TAVALISSE dose could be increased to 150 mg twice daily after one month. In the placebo controlled studies, the median duration of TAVALISSE exposure in these studies was 86 days (range 8 to 183) .
In the ITP double-blind studies, serious adverse drug reactions were febrile neutropenia, diarrhea, pneumonia, and hypertensive crisis, which each occurred in 1% of patients receiving TAVALISSE. ā¦
Drug interactions
Strong CYP3A4 Inhibitors
Concomitant use with strong CYP3A4 inhibitors increases exposure to R406 (the major active metabolite), which may increase the risk of adverse reactions. Monitor for toxicities of TAVALISSE that may require dose reduction when given concurrently with a strong CYP3A4 inhibitor .
Strong CYP3A4 Inducers
Concomitant use with a strong CYP3A4 inducer reduces exposure to R406. Concomitant use of TAVALISSE with strong CYP3A4 inducers is not recommended .
CYP3A4 Substrates
Concomitant use of TAVALISSE may increase concentrations of some CYP3A4 substrate drugs. Monitor for toxicities of CYP3A4 substrate drug that may require dosage reduction when given concurrently with TAVALISSE .
BCRP Substrates
Concomitant use of TAVALISSE may increase concentrations of BCRP substrate drugs (e.g., rosuvastatin). Monitor for toxicities of BCRP substrate drug that may require dosage reduction when given concurrently with TAVALISSE .
P-Glycoprotein (P-gp) Substrates
Concomitant use of TAVALISSE may increase concentrations of P-gp substrates (e.g., digoxin). Monitor for toxicities of the P-gp substrate drug that may require dosage reduction when given concurrently with TAVALISSE .
About this medicine
Fostamatinib is a tyrosine kinase inhibitor. TAVALISSE is formulated with the disodium hexahydrate salt of fostamatinib, a phosphate prodrug that converts to its pharmacologically active metabolite, R406, in vivo.
The chemical name for fostamatinib disodium hexahydrate is disodium (6-[[5-fluoro-2-(3,4,5-trimethoxyanilino) pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxo-pyrido[3,2-b][1,4]oxazin-4-yl)methyl phosphate hexahydrate. The molecular formula is C23H24FN6Na2O9Pā6H2O, and the molecular weight is 732.52. The structural formula is:
Fostamatinib disodium is a white to off-white powder that is practically insoluble in pH 1.2 aqueous buffer, slightly soluble in water, and soluble in methanol.
Each TAVALISSE oral tablet contains 100 mg or 150 mg fostamatinib, equivalent to 126.2 mg or 189.3 mg fostamatinib disodium hexahydrate, respectively.
The inactive ingredients in the tablet core are mannitol, sodium bicarbonate, sodium starch glycolate, povidone, and magnesium stearate. ā¦
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 21149cc3-049b-43e2-b141-c9499160556c. Read the full official label on DailyMed.